Novo Nordisk | driving change to defeat serious chronic diseases
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
Careers - Novo Nordisk
At Novo Nordisk, you will have the opportunity to build a life-changing career in a global business environment. Join us and make a difference.
Find a job - Novo Nordisk
Build a life-changing career in a global business environment. Novo Nordisk offers a broad range of job opportunities across borders and job functions.
Our medicines | Diabetes medications | Obesity medication - Novo …
In some cases, healthcare professionals and patients can visit local Novo Nordisk websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources.
News Details - novonordisk.com
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.
What we do - Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in serious chronic disease treatment.
Novo Nordisk - Vbrick Rev™
Novo Nordisk - Vbrick Rev™ is a platform for live streaming and video content management.
MoMo
MoMo is a ‘ one stop data insight shop ’ enabling real-time, prescriptive, and action-driven site monitoring for all CRAs across Novo Nordisk therapeutic areas.
Who we are - Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes and obesity.
Q3 2024 presentation - investor.novonordisk.com
Q3 2024 presentation. 16 Investor presentation First nine months of 2024 R&D milestones Project Q3 2024 Diabetes care FLOW (CKD, Sema 1.0 mg) CN submissio IcoSema STRIDE (PAD, Sema 1.0 mg) Phase 3 resul SOUL (CVOT, Oral sema 14 mg) Monlunabant (INV-202) (DKD) Amycretin Phase 2 initiati Obesity care STEP HFpEF (Sema 2.4 mg) EU positive opin STEP 9 …